Arvee Laboratories (India) Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
ARVEE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.4 pts more than Nifty Microcap 250 and 4.8 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Arvee Laboratories approved its unaudited financial results for the quarter and nine months ended December 31, 2025. Q3 FY26 revenue from operations stood at ₹977.95 lakhs, up about 10% YoY from ₹890.85 lakhs, while quarterly profit after tax jumped to ₹182.69 lakhs from ₹15.48 lakhs — though a large chunk of this came from a ₹66.09 lakh deferred tax credit. On a 9-month basis, however, revenue from operations dropped sharply to ₹2,071.00 lakhs from ₹3,203.72 lakhs, a decline of roughly 35% YoY. Nine-month profit after tax was almost flat at ₹200.61 lakhs versus ₹207.82 lakhs last year. The non-textile (chemicals) segment drove the bulk of revenue and profits, while the textile segment contributed only around ₹109.71 lakhs in Q3. Statutory auditor Nirav Patel & Associates issued an unqualified limited review report.
Mixed picture for shareholders: the sharp YoY revenue contraction over 9 months is a clear negative, but margins and profits have expanded meaningfully on a lower base, and the strong sequential recovery in Q3 may lift sentiment. Watch for whether the revenue decline stabilises in Q4 and whether margin gains are sustainable.